Biotree Biomedical Completes Nearly RMB 100 Million Series A Funding Round Led by Qiming Venture Partners

VCBeat (WeChat: vcbeat) learned at the earliest opportunity that,Specialized and Innovative Metabolomics EnterpriseShanghai Biotree BIOTECH Co., Ltd.(hereinafter referred to as"Biotree BIOTECH") Announced CompletionSeries A Financing of Nearly RMB 100 Million, this round of financing was led byQiming Venture PartnersSole Lead Investor.

The financing proceeds will be primarily used for Shanghai Biotree BIOTECH Co., Ltd.Expansion of the Instrument Platform for Metabolomics Research Services, and R&D and Production of Detection Reagents, while continuing to expand Shanghai Biotree BIOTECH's technological advantages in the metabolomics market, promote the integration of metabolomics with proteomics and other multi-omics technologies, accelerate the clinical translation of metabolomics products, and drive the rapid development of mass spectrometry in the life sciences field.

Shanghai Biotree BIOTECH Co., Ltd. (formerly “Aiqu Biology”) was established in 2012 at the Fudan University Science and Technology Entrepreneurship Demonstration Park in Shanghai. The company aims to conduct multi-omics research, including metabolomics and proteomics, on biological samples from humans, animals, plants, and microorganisms. It transforms research findings into innovative products for early screening or diagnosis in clinical and general health applications through its core technologies, thereby improving quality of life. Focusing on the application of innovative mass spectrometry technologies in life sciences and medical health, Biotree is committed to becoming an authoritative testing and analysis institution in the broader life sciences field. After ten years of development, Biotree has now established a comprehensiveResearch Services, Pharmaceutical Company Services, Clinical Mass Spectrometry ServicesandBig Data Information Service Platform.

Biotree’s founding team hails from prestigious institutions such as Fudan University and the Chinese Academy of Sciences. With over a decade of deep expertise in metabolomics technology, the company is headquartered in Shanghai with a global outlook. Leveraging R&D, production, and service facilities spanning thousands of square meters, Biotree has established comprehensive analytical platforms for untargeted metabolomics, high-throughput targeted metabolomics, lipidomics, metabolic flux analysis, proteomics, and antibody sequencing, pioneering the scientific research services market for metabolomics in China.

Shanghai Biotree BIOTECH's business and services have covered all provinces and cities in China, Hong Kong, Macao, Taiwan, and overseas regions, withMore than 1,500Universities, research institutes, hospitals, pharmaceutical companies, and food enterprises have established long-term and stable cooperative relationships.The compound annual growth rate reached 70%.

Qiming Venture Partners, established in 2006, has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages 11 U.S. dollar funds and seven RMB funds, with total assets under management reaching $9.4 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.

To date, Qiming Venture Partners has invested in more than 480 high-growth innovative companies, of which over 180 have achieved exits through listings on exchanges such as the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange (HKEX), the Shanghai Stock Exchange (SSE), and the Shenzhen Stock Exchange (SZSE), as well as through mergers and acquisitions. More than 70 of these portfolio companies have become industry-recognized unicorns and super unicorns.